期刊文献+

NF-κB受体激活因子配体的表达及其多克隆抗体的制备 被引量:1

Expression of porcine receptor activator for nuclear factor-κB ligand in Escherichia coli and preparation of its polyclonal antibody
原文传递
导出
摘要 为获取猪源NF-k B受体激活因子配体(RANKL)及其抗体,根据GenBank中猪源RANKL的序列设计引物,将合成的RANKL基因克隆至pMAL-C4x表达载体,转化到大肠杆菌DH5α。经PCR和双酶切鉴定后测序分析,将阳性克隆转化至大肠杆菌BL21后通过IPTG诱导表达。优化表达条件,确定是包涵体表达,蛋白大小为78.1 ku。使用纯化的RANKL为抗原免疫兔制备多克隆抗体。构建重组质粒pCMV-RANKL,表达目的蛋白并使其与多克隆血清反应。经ELISA、Western-blot和IFA鉴定,证实抗RANKL多克隆抗体有良好的抗原特异性,为后续黏膜免疫的研究奠定了基础。 In order to obtain porcine nuclear factor-κB ligand(RANKL) and its antibodies,primers were designed according to the sequence of porcine RANKL in Gen Bank.The RANKL gene was cloned into p MAL-C4x expression vector and transformed into Escherichia coli DH5α.After identification by PCR,double enzyme digestion and sequencing,the positive clones were transformed into E.coli BL21 and induced by IPTG.After optimization of the induction conditions,the protein was expressed in inclusion bodies and the molecular weight was about 78.1 ku.Subsequently,the purified RANKL protein was used to immunize rabbit subcutaneously for preparation of anti-RANKL polyclonal antibody(Pc Ab).Coding RANKL was subcloned into pCMV-Myc plasmid,the expressed protein reacted with polyclonal antibody.Identified by ELISA,Western-blot and IFA,anti-RANKL PcAb has good antigen specificity,it is helpful for the follow-up study of mucosal immunity.
作者 耿抒贤 刘果 张娜 刘旻翾 燕苗苗 金丽 曾巧英 刘光亮 GENG Shu-xian;LIU Guo;ZHANG Na;LIU Min-xuan;YAN Miao-miao;JIN Li;ZENG Qiao-ying;LIU Guang-liang(College of Veterinary Medicine,Gansu Agricultural University,Lanzhou 730070,China;State Key Laboratory of Veterinary Etiology/Lanzhou Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Lanzhou 730046,China)
出处 《中国兽医科学》 CAS CSCD 北大核心 2020年第4期473-478,共6页 Chinese Veterinary Science
基金 国家自然科学基金项目(31572498,31702209) 国家重点研发计划项目(2016YFD500100)。
关键词 猪RANKL 原核表达 多克隆抗体 porcine RANKL prokaryotic expression polyclonal antibody
  • 相关文献

参考文献2

二级参考文献15

  • 1Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modehng and remodeling [J].Arch Biochem Biophys, 2008, 473 (2): 139-146.
  • 2Rauner M, Sipos W, Pietschmann P. Osteoimmunology [J]. Int Arch Allergy Immunol, 2007, 143 ( 1 ) : 31-48.
  • 3Arran J, Choi Y. Bone versus immune system [J]. Nature, 2000, 408 (6812): 535-536.
  • 4Keams AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remod- eling in health and disease [J].Endocr Rev, 2008, 29 (2): 155- 192.
  • 5Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development [J]. Dev Cell, 2002, 2 (4): 389- 406.
  • 6Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].Cell, 1998, 93 (2): 165-176.
  • 7Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early post- menopausal women [J].J Clin Invest, 2003, 111 ( 8 ) : 1221 - 1230.
  • 8Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology [J]. Ann N Y Acad Sci, 2008, 1143 (1): 123-150.
  • 9Dote RK. The RANKL pathway and Denosumab [J].Rheum Dis Clin North Am, 2011, 37 (3): 433-452.
  • 10Kim JM, Jeong D, Kang HK, et al. Osteoclast precursors display dynamic metabolic shifts toward accelerated glucose metabolism at an early stage of RANKL-stimulated osteoclast differentiation [J]. Cell Physiol Biochem, 2007, 20 (6): 935-946.

共引文献2

同被引文献3

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部